Previous Page  9 / 23 Next Page
Information
Show Menu
Previous Page 9 / 23 Next Page
Page Background

Page 40

A n n u a l S u mm i t o n

Hepatology and Pancreatic

Diseases

November 12-13 , 2018

Par i s , France

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Hepatology and Pancreatic Diseases 2018

Background:

Hepatitis C Virus (HCV) infection is an important health issue and leading cause of chronic liver disease in developing

countries including Pakistan. Therefore, the current study was aimed to assess the treatment responses of available antiviral

regimens.

Methods:

A total of 144 chronic HCV positive patients by real time PCR were enrolled from Department of Gastroenterology,

Pakistan Institute of Medical Sciences (PIMS), Islamabad (North Region), Pakistan. Treatment responses among chronic HCV

positive patients were observed for antiviral regimens. These antiviral regimens were Sofosbuvir + Ribavirin (24 weeks) and

Sofosbuvir + Daclatasvir (12 Weeks). Sofosbuvir (400 mg), (Sovaldi , Gilead Sciences, USA) and Daclatasvir (60 mg ), (MyDekla,

Mylan , USA/Dacklinza, Bristo Myers Squibb, USA) were prescribed to take orally once a day. In addition, Ribavirin (Xolox,

Ferozsons, Pakistan), (400 mg or 600 mg ) had been advised to take orally twice daily on the basis of weight of patients. The end

of treatment response (ETR) after completion of treatment and sustained virological response (SVR) after 12 weeks of cessation

of treatment were assessed by the detection of HCV RNA in sera of treated patients.

Results:

The high ETR and SVR were achieved with Sofosbuvir + Daclatasvir (12 weeks), (92.26%, 71/73) when compared with

Sofosbuvir + Ribavirin (24 weeks), (84.50%, 60/71) among chronic HCV positive patients.

Conclusions:

In conclusion, the 12 weeks HCV antiviral eradication regimen i.e., Sofosbuvir + Daclatasvir was more effective,

economic and a better choice than 24 weeks regimen ‘Sofosbuvir + Ribavirin’ in our region.

ahmedtanveer17@yahoo.com

12 Weeks Hepatitis C Virus Antiviral Regimen is

a Better Choice than 24 Weeks Regimen in North

Region of Pakistan

Tanveer Ahmed

1

, Mashhood Ali

1

, Faisal Rasheed

2

1

Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan

2

Pakistan Institute of Nuclear Science and Technology, Pakistan

J Clin Gastroenterol Hepatol 2018, Volume:2

DOI: 10.21767/2575-7733-C3-009